Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by Dwizellon Oct 05, 2018 2:07pm

142 Views

Post# 28753833

RE:Sales projection 4th quarter (Trogarzo)

We already know it was 2.5 million (37011000 TWD *.042 / by .62) in september (+- the inventory variance, but should not be material).

So I guess a total of 10.5 million for the quarter .... (8 M in 2 months) ... I think it's realistic with more insurances on board and with a thiner delay for the paper work ...

Egrifta should be arorund 13 ... so total sale of 23.5 M

What are the Great analysts projections for the period ?

Bullboard Posts

Changing Europe’s dependency on HREE from China